Cyclin D1 regulates G1 cell-cycle progression and is aberrantly expressed in carcinogenesis. Proteasomal degradation of cyclin D1 was highlighted as a cancer chemopreventive mechanism. To understand this mechanism better, residues responsible for degradation and ubiquitination of cyclin D1 were investigated. Eighteen lysines in cyclin D1 had single, double or multiple mutations engineered before transfection into BEAS-2B human bronchial epithelial (HBE) cells to evaluate stabilities after all-trans-retinoic acid (RA) or cycloheximide treatments. Specific mutations stabilized cyclin D1, including substitutions of lysines surrounding the cyclin box domain that inhibited RA-mediated degradation and extended the cyclin D1 half-life. Mutation of all cyclin D1 lysines blocked polyubiquitination. N-terminus (but not C-terminus) modification stabilized cyclin D1. Ubiquitination-resistant mutants preferentially localized cyclin D1 to the nucleus, directly implicating subcellular localization in regulating cyclin D1 degradation. Taken together, these findings uncover specific residues conferring ubiquitination of cyclin D1. These provide a mechanistic basis for proteasomal degradation of cyclin D1.
Introduction
Cyclin D1 is a critical G1-S cell-cycle regulator. Aberrant cyclin D1 expression commonly occurs in human cancers, as reviewed (Diehl, 2002) . Inhibition of cyclin D1 degradation inhibits G1 arrest and renders cells susceptible to DNA damage, promoting carcinogenesis (Agami and Bernards, 2000) . The AA genotype of the A870G cyclin D1 polymorphism is linked to increased cancer risk from resistance to its proteasomal degradation (Solomon et al., 2003) . Certain antineoplastic agents repress cyclin D1 through transcriptional as well as post-transcriptional mechanisms (Langenfeld et al., 1997; Dragnev et al., 2001 Dragnev et al., , 2004 Aggarwal et al., 2004; Patel et al., 2005) . All-trans-retinoic acid (RA) induces proteasomal degradation of cyclin D1 in BEAS-2B human bronchial epithelial (HBE) cells (Langenfeld et al., 1997; Dragnev et al., 2004) and NT2/D1 human embryonal carcinoma cells (Spinella et al., 1999) . This degradation was proposed as a retinoid chemopreventive and differentiation-inducing mechanism (Langenfeld et al., 1997; Spinella et al., 1999) .
Cyclin D1 is a short-lived protein. Its turnover is affected by physiologic and pathologic states. Cyclin D1 motifs are associated with its degradation. When cells are subjected to genotoxic stress, cyclin D1 degradation is regulated by an RxxL destruction motif (Agami and Bernards, 2000) . Pharmacologic treatments can trigger cyclin D1 degradation through the ubiquitin-proteasome pathway, and this is positively regulated by glycogen synthase kinase-3b (GSK3b)-dependent phosphorylation of cyclin D1 at threonine-286 (Diehl et al., 1997) . An alanine substitution of this residue inhibits cyclin D1 polyubiquitination (Diehl et al., 1997) . We reported that RA-mediated cyclin D1 degradation is governed by the ubiquitin-proteasome system in several cell contexts (Langenfeld et al., 1997; Spinella et al., 1999; Dragnev et al., 2004) . The proline glutamic acid serine threonine (PEST) domain plays a key role in this degradation (Langenfeld et al., 1997) . Alanine substitution for threonine-286 can antagonize RA-mediated cyclin D1 degradation (Spinella et al., 1999; Dragnev et al., 2004) .
In the ubiquitin-proteasome system, the first ubiquitin moiety is conjugated through its C-terminal glycine 76 residue to an e-NH 2 group of an internal lysine residue. For several proteins, an initial ubiquitin moiety is conjugated to the a-NH 2 group of the N-terminus (Ciechanover and Ben-Saadon, 2004 ). Ubiquitin-dependent degradation of cyclin D1 is well known. Yet, residues responsible for ubiquitination and targeting cyclin D1 for proteasomal degradation were not previously delineated.
This study explored the residues in human cyclin D1 responsible for its stabilization and ubiquitination. Lysines present in cyclin D1 were engineered with individual, double or multiple mutations; domains regulating degradation were found. Mutations of nine lysines flanking the cyclin box domain increased cyclin D1 stability. As expected, mutation of all cyclin D1 lysines blocked polyubiquitination. N-terminal, but not C-terminal modification stabilized cyclin D1. Functional consequences of these mutations were examined and revealed some promoted nuclear localization of cyclin D1. Taken together, these findings provide a mechanistic basis for cyclin D1 degradation through the ubiquitinproteasome pathway.
Results
Single and double lysine mutations of cyclin D1 Mutation of lysines was hypothesized to confer resistance to cyclin D1 proteolysis by preventing its ubiquitination. To map cyclin D1 ubiquitination site(s), each of the 18 lysines (K) of cyclin D1 ( Figure 1a ) was substituted for an arginine (R) by site-directed mutagenesis. For adjacent lysines, two arginine substitutions were engineered. Arginine was used to prevent a charge change in mutant proteins.
Effects of mutations on cyclin D1 degradation were examined using RA treatment, since this can cause cyclin D1 proteasomal degradation (Langenfeld et al., 1997; Spinella et al., 1999) . BEAS-2B HBE cells were independently transiently transfected with indicated hemagglutinin (HA)-tagged lysine-mutated cyclin D1 species, and treated with or without RA. Immunoblot analyses ( Figure 1b) and quantification of signals ( Figure 1c ) uncovered several lysine mutations including K 33 R, K 95,96 R, K 112,114 R that inhibited repression of these cyclin D1 species, despite RA-treatment. The K 112,114 R mutation prominently inhibited this degradation.
Turnover rates of single or double lysine mutants of cyclin D1 were next analysed after transient transfection into BEAS-2B HBE cells. The half-life of each cyclin D1 species was determined without or with cycloheximide (CHX) treatment to inhibit de novo protein synthesis. Figure 1d demonstrated specific lysine mutations, such as K 112,114 R and K 269 R, which increased half-lives as compared with wild-type cyclin D1. The combined mutation of K 112,114,269 R had similar stability as K 112,114 R (see Supplementary Figure 1 ). K112 and K114 regulated cyclin D1 stability after RA and CHX treatments (Figure 1b-d) . To determine whether K112 and K114 were sites of ubiquitination, BEAS-2B HBE cells were transiently co-transfected with the described ubiquitin expression plasmid along with wild-type cyclin D1 or mutant K 112,114 R cyclin D1 species. Transfectants were treated with the proteasome inhibitor, N-acetylleucyl-leucyl-norleucinal (ALLN). ALLN treatment confirmed polyubiquitination of wild-type and K 112,114 R cyclin D1 species (Figure 1e ). Similar ubiquitin conjugations were found in wild-type and this mutant cyclin D1 species, indicating residues K112 and K114 did not appreciably affect cyclin D1 ubiquitination. Thus, single or double lysine residue mutations exerted modest effects on cyclin D1 stability.
Multiple lysine mutations of cyclin D1
Single or double-lysine mutations did not substantially affect cyclin D1 proteolysis. This was not unexpected. Polyubiquitination is often anchored on multiple lysines (Ciechanover, 1994) . To uncover lysines targeted for ubiquitination, sequential lysine mutations were engineered in cyclin D1, as displayed in Figure 2a . These mutant cyclin D1 species were each transfected into BEAS-2B HBE cells followed by vehicle, RA or CHX treatments as in Figure 1 . Immunoblot analyses reveal effects of mutations on RA-dependent cyclin D1 degradation (Figure 2b ). After normalization with a co-transfected enhanced green fluorescent protein (EGFP) vector, expression of wild-type and indicated mutant cyclin D1 species were quantified as in Figure 2c . Multiple mutations involving nine lysines from K33 to K114 substantially stabilized cyclin D1 protein, despite RA treatment. Mutations of remaining lysines conferred even greater cyclin D1 stabilization. Turnover rates of cyclin D1 species were analysed with CHX treatments in Figure 2d . As expected, multiple lysine mutations in K 33-114 R substantially increased half-life relative to wildtype cyclin D1. Indeed, lysine-less cyclin D1 (K 33-269 R) was quite stable.
To determine whether these lysine mutations conferred resistance to ubiquitination, BEAS-2B HBE cells were co-transfected with ubiquitin-expressing plasmids and HA-tagged lysine-mutated cyclin D1 species. Cells were subjected to immunoblot or immunoprecipitation assays in the presence and absence of ALLN treatment. Immunoblot analyses were performed to search for ubiquitinated species (Figure 3a) . Polyubiquitination was markedly repressed in K 33-238 R cyclin D1 with 17 lysines substituted. Lysine-less K 33-269 R cyclin D1 exhibited even greater resistance to ubiquitination. Similar findings followed HA immunoprecipitation and immunoblot analysis with an antiubiquitin antibody ( Figure 3b ).
K 33-269 R mutation of cyclin D1 and nuclear localization Following growth-factor stimulation, cyclin D1 is localized in the nucleus during the G1 phase and exits the nucleus as cells progress through S phase (Baldin et al., 1993) . Transversion of threonine-286 to an alanine (T286A) inhibits a key phosphorylation event that confers cyclin D1 resistance to polyubiquitination, resulting in a longer half-life relative to wild-type cyclin D1 (Diehl et al., 1997; Dragnev et al., 2004; Ma et al., 2005) . This mutation inhibits cyclin D1 nuclear export (Diehl et al., 1997 (Diehl et al., , 1998 . In this study, threonine-286 of cyclin D1 was not mutated. It was hypothesized that lysine-less cyclin D1 (K 33-269 R) would exert similar effects on cyclin D1 nuclear localization as the T286A mutation. An immunocytochemistry assay confirmed K 33-269 R cyclin D1 was preferentially localized to the nucleus relative to transfected wild-type cyclin D1 (Figure 4a ). For wild-type cyclin D1 26% of cells had nuclear localization of cyclin D1. In contrast, 72% of K 33-269 R cyclin D1-expressing cells exhibited nuclear localization of cyclin D1, as in Figure 4b . Other lysine substitutions stabilized cyclin D1 and preferentially localized these species to the nucleus (Supplementary Figure 2) . N-terminal modification and cyclin D1 stability N-terminal ubiquitination of certain proteins occurs (Ciechanover and Ben-Saadon, 2004 ). The polyubiquitin chain conjugates to the a-NH 2 group of the N-terminus of a target protein (Ciechanover and Ben-Saadon, 2004) . N-terminal modification can prevent ubiquitination (Coulombe et al., 2004) . In this study, independent EGFP modifications of the N-and C-termini of cyclin D1 were engineered and species were transiently Twenty-four hours after transfection, BEAS-2B cells were treated with CHX (40 mg/ml) for indicated time points. Immunoblot analyses were performed using an anti-HA antibody and with signal quantification relative to transfected EGFP expression. Half-lives (min) for cyclin D1 species were calculated using Sigmaplot software. (e) Polyubiquitination (Ub conjugation) of wild-type (WT-D1) and mutant (K 112,114 R) cyclin D1. BEAS-2B cells were transfected with a ubiquitin-expression vector and either HA-tagged wild-type (WT-D1) or (K 112,114 R) cyclin D1 species. Twenty-four hours after transfection, cells were treated with ALLN (100 mM) or vehicle for 6 h. Immunoblot analyses were performed using an anti-HA antibody.
Regulation of cyclin D1 ubiquitination Q Feng et al transfected into BEAS-2B HBE cells followed by RA or vehicle treatments. Only the N-terminal modification partially stabilized cyclin D1 (Figure 5a ). Following treatments with CHX, the N-terminal-modified species exhibited a longer half-life than wild-type cyclin D1, indicating that the N-terminus contributed to stabilization of cyclin D1 (Figure 5b ). Less abundant, lowmolecular-weight cyclin D1 species in Figure 5b , likely represent minor post-translational products.
Discussion
Prior work uncovered proteasomal degradation of cyclin D1 as a chemopreventive mechanism of retinoids and other agents (Langenfeld et al., 1997; Spinella et al., 1999; Dragnev et al., 2001 Dragnev et al., , 2004 ). The precise mechanisms for this ubiquitin-dependent degradation were not determined. Cyclin D1 residues that were ubiquitinmodified to signal proteasomal degradation had not been identified and this study determined this. Lysines are recognized as polyubiquitination sites, but few proteins have had these sites identified. For example, lysines 21 and 22 of IkBa are modified by ubiquitin (Scherer et al., 1995) . Lysine 133 is important for ubiquitin-dependent degradation of MyoD (Batonnet et al., 2004) . Analyses of ubiquitinated cyclin B reveal that multiple lysines act as ubiquitin-acceptor sites; mutagenesis indicated that no single lysine was essential for cyclin B degradation (King et al., 1996) . Twenty-four hours after transfection, BEAS-2B cells were treated with CHX (40 mg/ml) for indicated time points. Half-lives (minutes, min) for depicted cyclin D1 species were calculated using Sigmaplot software.
Regulation of cyclin D1 ubiquitination Q Feng et al
This study adds to prior work by determining ubiquitination sites within human cyclin D1. Certain single or double lysine substitutions affected cyclin D1 degradation, but these did not alter cyclin D1 ubiquitination. Substitution of K112 or K114 for glutamine blocks CDK4/6 activation (Kobayashi et al., 1992) . As expected, K 112,114 R mutation of cyclin D1 did not bind CDK4 (data not shown). Turnover of cyclin D1 depends on phosphorylation by GSK-3b; GSK-3b is reported to phosphorylate cyclin D1 when bound to CDK4 (Diehl et al., 1998) . Observed stabilization of K 112,114 R cyclin D1 was consistent with this prior work. Polyubiquitination of K 112,114 R cyclin D1 can occur since free cyclin D1 protein undergoes ubiquitination (Germain et al., 2000) .
Findings reported here reveal multiple lysine mutations stabilized cyclin D1. Some cyclin D1 mutants (such as K 33-167 R, K 33-180 R and K 33-194 R) are stabilized (Figure 2b-d) , but still undergo ubiquitination. Similarly, the PEST sequence is required for degradation of c-myc, but not for ubiquitination (Gregory and Hann, 2000) . Cyclin A-cyclin B fusion proteins are stabilized, but are still ubiquitinated (Klotzbucher et al., 1996) . Several stable cyclin A mutants are ubiquitinated perhaps due to ubiquitination being shifted to cryptic sites (Fung et al., 2005) . This might occur in some cyclin D1 mutants described here. Cyclin D1 ubiquitination may involve the anaphase-promoting complex (APC) (Peters, 2002) . Future work should determine how cyclin D1 ubiquitination confers degradation.
Phosphorylation signals ubiquitination and triggers proteasomal degradation of specific proteins, such as IkBa (DiDonato et al., 1996) and p53 (Chernov et al., 2001 ). Threonine-286 within the PEST domain of cyclin D1 is a site affecting ubiquitin-dependent proteolysis of cyclin D1 (Diehl et al., 1997) . Inhibition of phosphorylation at threonine-286 inhibits cyclin D1 degradation (Diehl et al., 1997) . In this study, without threonine-286 substitution, indicated lysine and N-terminal-modified cyclin D1 species inhibited cyclin D1 degradation. Both phosphorylation and ubiquitination affect cyclin D1 stability. How these cooperate to regulate cyclin D1 stability needs to be learned.
Cyclin D1 subcellular localization affects cell-cycle progression (Baldin et al., 1993) . Cyclin D1 accumulates in the nucleus throughout G1, but it translocates to the cytoplasm during interphase (Baldin et al., 1993) . Phosphorylation of cyclin D1 at threonine-286 promotes its ubiquitination and affects subcellular localization (Alt et al., 2000) . Association of cyclin D1 with nuclear exportin CRM1 facilitates GSK-3b-dependent phosphorylation and promotes cyclin D1 nuclear export (Alt et al., 2000) . The cyclin D1 T286A mutation reduces binding to CRM1, causing it to remain in the nucleus throughout the cell cycle (Alt et al., 2000) . This study reveals cyclin D1 lysine mutations from residues 33 to 269 confer resistance to ubiquitin-dependent degradation at least partly by promoting nuclear localization. How ubiquitination regulates cyclin D1 localization and interaction with nuclear exportin CRM1 are subjects for future work.
Cyclin D1 localization impacts carcinogenesis (Gladden and Diehl, 2005) . Expression of nuclearlocalized T286A cyclin D1 species in murine fibroblasts causes cellular transformation and tumor cell growth in immune-compromised mice (Alt et al., 2000 ). An Regulation of cyclin D1 ubiquitination Q Feng et al alternative cyclin D1 isoform, cyclin D1b, exerts potent oncogenic effects. It transforms NIH-3T3 cells with greater efficiency than wild-type cyclin D1 perhaps owing to its nuclear localization (Lu et al., 2003) . Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a tumor suppressor that induces cell-cycle arrest by decreasing cyclin D1 expression and nuclear localization; this may affect carcinogenesis (Radu et al., 2003) . In contrast to the C-terminus, this study uncovered a role for N-terminal modification in regulating cyclin D1 stability. Inhibition of polyubiquitination was undetected in this cyclin D1 species after ALLN treatment (data not shown). A single residue substitution might not be recognized as an anchor for ubiquitination.
Cyclin D1 is a candidate therapeutic target (Petty et al., 2003) . Understanding how cyclin D1 degradation occurs is important. Tumor cell differentiation or growth suppression induced by retinoid or rexinoid (retinoid X receptor, RXR) treatments cause cyclin D1 proteolysis (Spinella et al., 1999; Dragnev et al., 2004) . Microarray analyses identified UBE1L, an E1-like ubiquitin-activating enzyme, as a retinoid target gene that triggers cyclin D1 repression (Pitha-Rowe et al., 2004b) . UBE1L is involved in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia (Kitareewan et al., 2002; Pitha-Rowe et al., 2004a) . Whether UBE1L-mediated repression of cyclin D1 is through ISGylation should be investigated.
Combination therapy is a tenet of clinical cancer therapy and chemoprevention (Dmitrovsky and Sporn, 2002) . An attractive strategy is to use different agents to target the same oncogenic product through independent mechanisms. Clinical validation for targeting cyclin D1 comes from positive results of a phase I trial combining an epidermal growth factor receptor-tyrosine kinase inhibitor with a rexinoid in advanced aerodigestive tract cancers (Dragnev et al., 2005) . The findings reported here provide a mechanistic basis for selection of agents used alone or in combination to degrade cyclin D1 and confer antineoplastic effects.
This study uncovered ubiquitination sites that affect cyclin D1 stability. Retinoid repression of wild-type, but not K 33-269 R cyclin D1 protein, was confirmed in another cell context, NT2/D1 human embryonal carcinoma cells (data not shown). This underscores the relevance of these findings beyond HBE cells. Figure 6 summarizes cyclin D1 sites that affect its degradation. Both phosphorylation-and ubiquitin-dependent mechanisms regulate cyclin D1 turnover. Multiple lysines within cyclin D1 undergo ubiquitination and engage proteasomal degradation. These findings advance an understanding of mechanisms that affect cyclin D1 stability.
Materials and methods
Cell lines and reagents BEAS-2B HBE cells were cultured in LHC-9 media (Biofluids, Rockville, MD, USA) at 371C in a humidified incubator with 5% CO 2 , as described (Langenfeld et al., 1997) . RA was purchased (Sigma, St Louis, MO, USA), as was the proteasome inhibitor, ALLN (Calbiochem, San Diego, CA, USA).
Plasmid construction, mutagenesis and transient transfection
The pRcCMV-cyclin D1-HA plasmid was provided by Dr Steven Dowdy (Howard Hughes Medical Institute, Washington University School of Medicine). The C-terminus of cyclin D1 was HA-tagged and did not alter cyclin D1 stability (Supplementary Figure 3) . Cyclin D1 transversions from lysines to arginines were generated using the QuickChange site-directed mutagenesis kit (Strategene, La Jolla, CA, USA). DNA sequence analyses confirmed each engineered species. N-terminal EGFP-tagged cyclin D1 was engineered with fulllength human cyclin D1 cDNA excised with BamHI/HindIII digestions of pRcCMV-cyclin D1-HA. The purified fragment Regulation of cyclin D1 ubiquitination Q Feng et al was inserted into BamHI and HindIII sites of pEGFP-C1 (Clontech, Palo Alto, CA, USA). C-terminal EGFP-tagged cyclin D1 species was engineered by inserting the excised cyclin D1-HA cDNA into XhoI and HindIII sites of pEGFP-N1 (Clontech, Palo Alto, CA, USA). DNA sequence analyses confirmed cloned species. BEAS-2B cells were transfected with indicated vectors using Effectene reagent (Qiagen, Valencia, CA, USA) and manufacturer's established techniques. Cotransfection with pEGFP-C1 controlled for transfection efficiency.
Immunoblot and immunoprecipitation analyses
Cells were lysed with ice-cold radioimmunoprecipitation (RIPA) lysis buffer, as described (Langenfeld et al., 1997) . Lysates were size-fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) before transfer to a nitrocellulose membrane (Schleicher and Schuell). The primary antibody was a murine monoclonal antibody that recognized HA (Babco, Richmond, CA, USA). For EGFP detection, membranes were stripped and incubated with an anti-GFP monoclonal antibody (Clontech, Palo Alto, CA, USA). Cyclin D1-HA lysates were immunoprecipitated with an anti-HA antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Cyclin D1-ubiquitin complexes were detected by immunoblotting with an anti-ubiquitin monoclonal antibody (Santa Cruz Biotechnology).
Half-life assay BEAS-2B cells were transiently transfected with cyclin D1 species. Twenty-four hours after transfection, cells were treated with CHX (40 mg/ml) for indicated lengths of time.
Lysates were subjected to immunoblot analyses. 
K112-114
Figure 6 Sites and domains that prominently affect cyclin D1 stability. Domains (boxes) that stabilize cyclin D1 are highlighted as are multiple lysines (solid lines), the N-terminus and threonine-286.
Regulation of cyclin D1 ubiquitination Q Feng et al

Immunocytochemistry
To compare subcellular localization of wild-type and mutant cyclin D1 species, transiently transfected BEAS-2B cells were fixed overnight in a phosphate-buffered saline solution containing 2% paraformaldehyde. Coverslipped cells were permeabilized with a 0.3% Triton X-100 phosphate buffered saline (PBS) solution, incubated with 5% blocking goat serum and immunostained with an anti-HA monoclonal antibody. Cells were then incubated for 1 h with green fluorescent goat anti-mouse antibody (Invitrogen, Carlsbad, CA, USA), rinsed with 0.3% Triton X-100 PBS and mounted with antifade solution containing 4 0 -6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA, USA). A Bio-Rad (Hercules, CA, USA) MRC-1024 Krypton/Argon laser confocal system was used for imaging with a Zeiss Axioskop upright microscope. The objective to acquire images was a Â 63 Plan Apo 1.4 NA.
